The novel class of GLP-1 receptor agonist and GIP dual medications, including tirzepatide, semaglutide, and the newly introduced retatrutide, offer significant improvements in diabetes management . https://tirzepatide410304.blog93.com/62094876/retatrutide-a-comparative-examination